E
Evosep
Develops new solutions to make clinical proteomics 100 times more robust and 10 times faster
About Evosep
Evosep is a pioneering company in the field of clinical proteomics, focusing on developing advanced solutions that significantly enhance the robustness and speed of proteomic analyses. The company serves a diverse range of clients, including clinical laboratories, research institutions, and pharmaceutical companies, who require high-throughput and reliable proteomic data. Operating in the rapidly growing proteomics market, Evosep's business model revolves around the sale of specialized instruments and consumables, such as the Evosep One and Evotip, which are designed to streamline and improve the efficiency of proteomic workflows. The company generates revenue through direct sales of these products, as well as through service contracts and partnerships. By addressing the increasing demand for high-throughput and robust proteomic solutions, Evosep aims to bridge the gap between research and clinical applications, ultimately bringing proteomics closer to everyday clinical practice.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Odense, Denmark
- Employees
- 88
- Open positions
- None listed
- Dealroom signal
- 80.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, proteomics, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2023 | $40M | $160M | Novo Nordisk | ↗ |
| OtherOther financing | Jun 2016 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Evosep is 11K monthly website visits, down 31.3% over the last three months. Evosep's team grew 11.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Novo Nordisk
Other known investors1 additional known investor
Export and Investment Fund of Denmark
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Evosep on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evosep’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.